Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma.

التفاصيل البيبلوغرافية
العنوان:	Survival rates according to barcelona clinic liver cancer sub-staging system after transarterial embolization for intermediate hepatocellular carcinoma.
المؤلفون:	Scaffaro LA; Leandro Armani Scaffaro, Radiology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil., Stella SF; Leandro Armani Scaffaro, Radiology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil., Alvares-Da-Silva MR; Leandro Armani Scaffaro, Radiology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil., Kruel CD; Leandro Armani Scaffaro, Radiology Division, Hospital de Clínicas de Porto Alegre, Porto Alegre 90035-903, Brazil.
المصدر:	World journal of hepatology [World J Hepatol] 2015 Mar 27; Vol. 7 (3), pp. 628-32.
نوع المنشور:	Journal Article
اللغة:	English
بيانات الدورية:	Publisher: Baishideng Publishing Group Country of Publication: United States NLM ID: 101532469 Publication Model: Print Cited Medium: Print ISSN: 1948-5182 (Print) NLM ISO Abbreviation: World J Hepatol Subsets: PubMed not MEDLINE
أسماء مطبوعة:	Publication: 2014- : Pleasanton, CA : Baishideng Publishing Group Original Publication: Beijing, China : Baishideng
مستخلص:	Aim: To investigate the survival rates after transarterial embolization (TAE). Methods: One hundred third six hepatocellular carcinoma (HCC) patients [90 barcelona clinic liver cancer (BCLC) B] were submitted to TAE between August 2008 and December 2013 in a single center were retrospectively studied. TAE was performed via superselective catheterization followed by embolization with polyvinyl alcohol or microspheres. The date of the first embolization until death or the last follow-up date was used for the assessment of survival. The survival rates were calculated using the Kaplan-Meier method, and the groups were compared using the log-rank test. Results: The overall mean survival was 35.8 mo (95%CI: 25.1-52.0). The survival rates of the BCLC A patients (33.7%) were 98.9%, 79.0% and 58.0% at 12, 24 and 36 mo, respectively, and the mean survival was 38.1 mo (95%CI: 27.5-52.0). The survival rates of the BCLC B patients (66.2%) were 89.0%, 69.0% and 49.5% at 12, 24 and 36 mo, respectively, and the mean survival was 29.0 mo (95%CI: 17.2-34). The survival rates according to the BCLC B sub-staging showed significant differences between the groups, with mean survival rates in the B1, B2, B3 and B4 groups of 33.5 mo (95%CI: 32.8-34.3), 28.6 mo (95%CI: 27.5-29.8), 19.0 mo (95%CI: 17.2-20.9) and 13 mo, respectively (P = 0.013). Conclusion: The BCLC sub-staging system could add additional prognosis information for post-embolization survival rates in HCC patients.
References:	Hepatology. 2011 Mar;53(3):1020-2. (PMID: 21374666) Cardiovasc Intervent Radiol. 2010 Feb;33(1):41-52. (PMID: 19908093) Semin Liver Dis. 2012 Nov;32(4):348-59. (PMID: 23397536) Gastroenterol Hepatol. 2014 Jul;37 Suppl 2:95-101. (PMID: 25087719) Cardiovasc Intervent Radiol. 2012 Oct;35(5):1119-28. (PMID: 22614031) J Gastroenterol Hepatol. 2015 Feb;30(2):358-63. (PMID: 25088668) World J Gastroenterol. 2014 Mar 28;20(12):3069-77. (PMID: 24695579) Cardiovasc Intervent Radiol. 2007 Jan-Feb;30(1):6-25. (PMID: 17103105) Lancet. 2002 May 18;359(9319):1734-9. (PMID: 12049862) J Vasc Interv Radiol. 2001 Mar;12(3):321-6. (PMID: 11287509) Br J Cancer. 2013 Apr 2;108(6):1252-9. (PMID: 23449352) Dig Liver Dis. 2013 Oct;45(10):852-8. (PMID: 23582346) J Gastroenterol Hepatol. 2014 Apr;29(4):787-93. (PMID: 24224567)
فهرسة مساهمة:	Keywords: Barcelona clinic liver cancer; Hepatocellular carcinoma; Subclassification; Transarterial embolization
تواريخ الأحداث:	Date Created: 20150408 Date Completed: 20150407 Latest Revision: 20220408
رمز التحديث:	20240628
مُعرف محوري في PubMed:	PMC4381186
DOI:	10.4254/wjh.v7.i3.628
PMID:	25848487
قاعدة البيانات:	MEDLINE

الوصف
تدمد:	1948-5182
DOI:	10.4254/wjh.v7.i3.628